To see all protocols that comply with the WHO Essential Medicine List 
Patients are at risk of adverse reactions to IV contrast which may require emergency intervention.
In an EMERGENCY call the EMERGENCY TEAM as per institutional policy.
Ensure radiation safety policies are adhered to at all times as per institutional guidelines.

This document provides information on the clinical procedure for the administration of intravenous (IV) contrast for radiotherapy simulation scans. Only health care professionals who have attained competency in intravenous cannulation and administration of contrast as per institutional guidelines should perform the included procedures. This document should be used in conjunction with expert clinical judgement and with individual institutional guidelines or policies.

The health care professional administering IV contrast (IV contrast administrator) should follow the relevant national and local institutional guidelines for the safe administration of IV contrast. The IV contrast administrator should be trained and competent in the relevant procedures including intravenous cannulation, IV contrast administration, the recognition of contrast media reactions, appropriate management, and resuscitation procedures including basic life support and have rapid access to staff competent in advanced life support. Administration of IV contrast should be in line with the relevant manufacturers’ product information and the TGA requirements including the contrast media, bottles/containers, syringes and all other components of the contrast delivery system.r

Non-vascular administration of contrast media (e.g. oral contrast) also has a risk of adverse events including hypersensitivity anaphylactic reactions. For information on hypersensitivity reactions please see Contrast administration for radiotherapy simulation scans.

This document should be read in conjunction with the following documents:

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

19 Dec 2018